ABBOTT LABORATORIES — Major Shareholding Notification 2010

Dec 10, 2010

SC 13G/A 1 a10-22345_2sc13ga.htm SC 13G/A

| UNITED
STATES |
| --- |
| SECURITIES
AND EXCHANGE COMMISSION |
| Washington,
D.C. 20549 |

*SCHEDULE 13G*

*Under the Securities Exchange Act of 1934 (Amendment No. 1)**

*Trubion Pharmaceuticals, Inc.*

(Name of Issuer)

*Common Stock, par value $0.001 per share*

(Title of Class of Securities)

*89778N102*

(CUSIP Number)

*October 28, 2010*

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
x	Rule 13d-1(c)
o	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

SEQ.=1,FOLIO='',FILE='C:\JMS\105933\10-22345-2\task4390587\22345-2-ba.htm',USER='105933',CD='Dec 10 21:02 2010'

CUSIP No. 89778N102 — 1	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Abbott Laboratories (36-0698440)
2	Check the Appropriate Box
if a Member of a Group (See Instructions)
	(a)	o
	(b)	o
3	SEC Use Only
4	Citizenship or Place of
Organization Illinois
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 0
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 0
9	Aggregate Amount
Beneficially Owned by Each Reporting Person 0
10	Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions) o
11	Percent of Class
Represented by Amount in Row (9) 0.0%
12	Type of Reporting Person
(See Instructions) CO

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105933\10-22345-2\task4390587\22345-2-ba.htm',USER='105933',CD='Dec 10 21:02 2010'

Item 1.	(a)	Name of Issuer: Trubion Pharmaceuticals, Inc.
	(b)	Address of Issuer’s
Principal Executive Offices: 2401 Fourth Avenue, Suite 1050 Seattle, WA 98121
Item 2.
	(a)	Name of Person Filing: Abbott Laboratories
	(b)	Address of Principal
Business Office, or if none, Residence: 100 Abbott Park Road Abbott Park, Illinois
60064-6400
	(c)	Citizenship: Illinois
	(d)	Title of Class of
Securities: Common Stock, par value $0.001 per share
	(e)	CUSIP Number: 89778N102
Item 3.	If this statement is filed pursuant
to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
	(a)	o	Broker or dealer
registered under section 15 of the Act (15 U.S.C. 78o);
	(b)	o	Bank as defined in section
3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	o	Insurance company as
defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	o	Investment company
registered under section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8);
	(e)	o	An investment adviser in
accordance with Rule 13d-1(b)(1)(ii)(E);
	(f)	o	An employee benefit plan
or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
	(g)	o	A parent holding company
or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
	(h)	o	A savings association as
defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);
	(i)	o	A church plan that is
excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); or
	(j)	o	Group, in accordance with
Rule 13d-1(b)(1)(ii)(J).

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105933\10-22345-2\task4390587\22345-2-ba.htm',USER='105933',CD='Dec 10 21:02 2010'

| Item 4. | Ownership. — (a) | Amount beneficially
owned: 0 shares | |
| --- | --- | --- | --- |
| | (b) | Percent of class: 0.0% | |
| | (c) | Number of shares as to
which the reporting person has: | |
| | | (i) | Sole power to direct the
vote: 0 |
| | | (ii) | Shared power to vote or
direct the vote: 0 |
| | | (iii) | Sole power to dispose or
direct the disposition of: 0 |
| | | (iv) | Shared power to dispose or
direct the disposition of: 0 |
| Item 5. | Ownership of Five Percent or Less
of a Class. | | |
| If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of securities, check
the following: x | | | |
| Item 6. | Ownership of More than Five Percent
on Behalf of Another Person. | | |
| Not applicable. | | | |
| Item 7. | Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company. | | |
| Not applicable. | | | |
| Item 8. | Identification and Classification
of Members of the Group. | | |
| Not applicable. | | | |
| Item 9. | Notice of Dissolution of Group. | | |
| Not applicable. | | | |
| Item 10. | Certifications. | | |
| Not applicable. | | | |

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105933\10-22345-2\task4390587\22345-2-ba.htm',USER='105933',CD='Dec 10 21:02 2010'

*SIGNATURE*

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 10, 2010
ABBOTT LABORATORIES
By:	/s/ Thomas C. Freyman
Name:	Thomas C. Freyman
Its:	Executive Vice President,
Finance
	and Chief Financial Officer

5

SEQ.=1,FOLIO='5',FILE='C:\JMS\105933\10-22345-2\task4390587\22345-2-ba.htm',USER='105933',CD='Dec 10 21:02 2010'